Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06563505
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-19
Brief Title:
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With RelapsedRefractory Marginal Zone Lymphoma
Sponsor:
Organization:
None